Li Yueming, Zhu Fanyou, Wen Rui, Hou Tingting, Xie Rou, Qin Jiao
Department of Rheumatology and Immunology, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, Hunan, People's Republic of China.
J Inflamm Res. 2024 Nov 14;17:8853-8860. doi: 10.2147/JIR.S479377. eCollection 2024.
Felty's syndrome (FS) is an uncommon disorder with a poor prognosis, and most patients die from infections caused by neutropenia. Currently, there is no standardized treatment strategy, and treatment options are based on case reports and clinical experience. To date, no cases of FS complicated by coronavirus disease-2019 (COVID-19) have been reported. This article reports a successful case of FS complicated by COVID-19. We emphasized treating rheumatic diseases with immunosuppressive therapy at appropriate doses based on strong and effective anti-infection when co-infected.
费尔蒂综合征(FS)是一种罕见的疾病,预后较差,大多数患者死于中性粒细胞减少引起的感染。目前,尚无标准化的治疗策略,治疗方案基于病例报告和临床经验。迄今为止,尚未有费尔蒂综合征合并2019冠状病毒病(COVID-19)的病例报道。本文报告了一例费尔蒂综合征合并COVID-19的成功病例。我们强调,在合并感染时,应在强力有效的抗感染治疗基础上,以适当剂量的免疫抑制疗法治疗风湿性疾病。